CN1919189A - Ibuprofen granule and preparing method thereof - Google Patents
Ibuprofen granule and preparing method thereof Download PDFInfo
- Publication number
- CN1919189A CN1919189A CN 200510090752 CN200510090752A CN1919189A CN 1919189 A CN1919189 A CN 1919189A CN 200510090752 CN200510090752 CN 200510090752 CN 200510090752 A CN200510090752 A CN 200510090752A CN 1919189 A CN1919189 A CN 1919189A
- Authority
- CN
- China
- Prior art keywords
- granule
- ibuprofen
- detect
- lives
- sweet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a novel ibuprofen granule and process for preparation, wherein the granule is prepared from 20 weight parts of ibuprofen and 80 weight parts of auxiliary materials, the auxiliary materials comprise the following constituents (by weight parts): starch gum 60-75 parts, hydroxyproxyl cellulose 2-10 parts, sodium cyclamate 1-7 parts. The process for preparing the granule comprises steps of disintegrating, sieving, making soft material, vacuum condensing and drying, finally granulating.
Description
Technical field
The present invention relates to a kind of preparation formulation of medicine, relate in particular to brufen pellet of a kind of sugar-free and preparation method thereof, belong to field of pharmaceutical preparations.
Background technology
Ibuprofen is a kind of drug for abating fever of determined curative effect, is extensive use of clinically.At present, the diabetics of China has exceeded more than 2,000 ten thousand, but existing brufen pellet all is a sugar-containing type, causes the fever patient who suffers from diabetes to take.For example, publication number is the patent application of CN 1135882A pharmaceutical formulation of disclosing a kind of brufen pellet and preparation method thereof, and this granule is prepared from by 20% ibuprofen, 20% dextrin and 60% cane sugar powder.Though this granule has advantages such as prescription is simple, preparation is easy, because used adjuvant is mainly cane sugar powder in the said preparation prescription, the fever patient who causes this granule to be not suitable for suffering from diabetes takes.So, prepare a kind of not sacchariferous brufen pellet and have important practical significance.
Summary of the invention
Technical problem to be solved by this invention is to overcome the deficiencies in the prior art, and a kind of brufen pellet of the determined curative effect that can take for the diabetes fever patient is provided.
Technical problem to be solved by this invention realizes by following technological approaches;
A kind of brufen pellet is made by the ibuprofen of 20 weight portions and the adjuvant of 80 weight portions, and wherein said adjuvant is grouped into by the one-tenth of following weight portion: dextrin 60-75 part, hyprolose 2-10 part and sodium cyclamate 1-7 part.
Be preferably: 5 parts of 70 parts in dextrin, 5 parts of hyprolose and sodium cyclamate.
Another technical problem to be solved by this invention provides a kind of method for preparing above-mentioned brufen pellet.
A kind of method for preparing above-mentioned brufen pellet may further comprise the steps:
1) take by weighing each composition by following weight portion:
The adjuvant of the ibuprofen of 20 weight portions and 80 weight portions, wherein adjuvant is grouped into by the one-tenth of following weight portion: dextrin 60-75 part, hyprolose 2-10 part and sodium cyclamate 1-7 part;
2) with dextrin, hyprolose and sodium cyclamate grinding and sieving, add the ibuprofen mix homogeneously again; Make soft material with purified water, make 16 order granules again;
3) vacuum condensation drying, 14 order granulate promptly.
In the above-mentioned preparation method, preferably dextrin, hyprolose and sodium cyclamate are pulverized the back and cross 120 mesh sieves.
Because cane sugar powder is a kind of main adjuvant of very sophisticated ibuprofen granule preparation, relatively good as main its stability of the preparation-obtained brufen pellet of adjuvant with it, curative effect is also relatively more definite.Still useless other adjuvant substitutes cane sugar powder and prepares the precedent of the ibuprofen granule preparation that has good stability in the prior art.The inventor tests through thousands of times hardships, final discovery is worked as with dextrin, hyprolose and sodium cyclamate as pharmaceutical adjunct, and when making up according to the weight portion of above-mentioned prescription with ibuprofen, preparation-obtained granule determined curative effect, have good stability, meet the stability requirement under the Chinese Pharmacopoeia item fully, abandon existing brufen pellet fully and made the defective of adjuvant with cane sugar powder, prepared granule does not contain sugar, suffers from the high fever patient of diabetes or blood glucose and can take fully yet.
In addition, granule of the present invention adopts the vacuum condensation method in the particle drying process, abandoned traditional oven drying method, can effectively prevent the smell pollution air, has eliminated pollution or infringement that surrounding and human body are caused.
In a word, granule of the present invention does not contain sugar and can take the advantage for diabetics except that having, advantage such as have still that preparation technology is simple, environmental protection, system easy to control the quality, medicine stability are good.
The specific embodiment
Further describe the present invention by the following examples, it should be understood that these embodiment only are used for the purpose of illustration, never limit the scope of the invention.
[embodiment 1]
Take by weighing each raw material (unit: g): ibuprofen 200, dextrin 700, hyprolose 50, sodium cyclamate 50 by following weight; Dextrin, hyprolose and sodium cyclamate are pulverized the back with pulverizer cross 120 mesh sieves, the ibuprofen that adds again after sieving mixed 40 minutes with three-dimensional mixer; Make soft material with purified water, make 16 order granules with granulator; With granule vacuum condensation drying, 14 order granulate, pack is promptly.
[embodiment 2]
Take by weighing each raw material (unit: g): ibuprofen 200, dextrin 630, hyprolose 100, sodium cyclamate 70 by following weight; Dextrin, hyprolose and sodium cyclamate are pulverized the back with pulverizer cross 120 mesh sieves, the ibuprofen that adds again after sieving mixed 40 minutes with three-dimensional mixer; Make soft material with purified water, make 16 order granules with granulator; With granule vacuum condensation drying, 14 order granulate, pack is promptly.
[embodiment 3]
Take by weighing each raw material (unit: g): ibuprofen 200, dextrin 750, hyprolose 30, sodium cyclamate 20 by following weight; Dextrin, hyprolose and sodium cyclamate are pulverized the back with pulverizer cross 120 mesh sieves, the ibuprofen that adds again after sieving mixed 40 minutes with three-dimensional mixer; Make soft material with purified water, make 16 order granules with granulator; With granule vacuum condensation drying, 14 order granulate, pack is promptly.
[embodiment 4]
Take by weighing each raw material (unit: g): ibuprofen 200, dextrin 720, hyprolose 40, sodium cyclamate 40 by following weight; Dextrin, hyprolose and sodium cyclamate are pulverized the back with pulverizer cross 120 mesh sieves, the ibuprofen that adds again after sieving mixed 40 minutes with three-dimensional mixer; Make soft material with purified water, make 16 order granules with granulator; With granule vacuum condensation drying, 14 order granulate, pack is promptly.
[test example] granule study on the stability of the present invention
According to two regulations of Chinese Pharmacopoeia version in 2000 about the medicine stability test guideline, to the prepared ibuprofen granule of the embodiment of the invention under temperature, humidity effect, time dependent rule is investigated, and establishes by accelerated tests and long term test the effect duration of medicine.
One, accelerated test
Get the prepared ibuprofen granule of the embodiment of the invention 1,2 and 3, press commercially available back,, placed 6 months under the condition of relative humidity 75% ± 5% 40 ℃ ± 2 ℃ of temperature.In 0th month, the 1st month, 2 months, 3 months, 6 each sampling at the end of month of duration of test once, detect by stable high spot reviews project.Testing result sees Table 1, table 2, table 3.
The granule accelerated test study on the stability result that table 1 embodiment 1 is prepared
| 0 month | 1 month | 2 months | 3 months | 6 months | |
| Character | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of |
| Content | 100.3％ | 100.2％ | 99.9％ | 100.0％ | 100.1％ |
| Granularity | Qualified | Qualified | Qualified | Qualified | Qualified |
| Limit test of microbe | 200/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 100/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 170/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 180/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 160/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect |
The granule accelerated test study on the stability result that table 2 embodiment 2 is prepared
| 0 month | 1 month | 2 months | 3 months | 6 months | |
| Character | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of |
| Content | 100.1％ | 100.4％ | 99.5％ | 100.1％ | 100.5％ |
| Granularity | Qualified | Qualified | Qualified | Qualified | Qualified |
| Limit test of microbe | 410/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 450/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 370/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 400/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 460/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect |
The granule accelerated test study on the stability result that table 3 embodiment 3 is prepared
| 0 month | 1 month | 2 months | 3 months | 6 months | |
| Character | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance: it is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of |
| Content | 100.9％ | 99.6％ | 100.3％ | 100.6％ | 100.0％ |
| Granularity | Qualified | Qualified | Qualified | Qualified | Qualified |
| Limit test of microbe | 360/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 380/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 370/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 320/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 360/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect |
Conclusion (of pressure testing): brufen pellet accelerated test of the present invention is stable, and three batches of test samples 40 ℃ ± 2 ℃ of temperature, were placed 6 months under the condition of relative humidity 75% ± 5%, every index all with test preceding no significant difference.Illustrate that brufen pellet of the present invention has good stability.
Two, long term test
Long term test is to carry out under the actual storage requirement near medicine.Get the prepared ibuprofen granule of the embodiment of the invention 1,2 and 4, be divided into three batches of test samples, press commercially available back,, place under the condition of relative humidity 60% ± 10% and observe 25 ℃ ± 2 ℃ of temperature.In 3rd month, 6 months, 9 months, 12 months, 18 each sampling at the end of month of duration of test once, detect by stable high spot reviews project.Its testing result sees Table 4, table 5, table 6.
The granule long term test study on the stability result that table 4 embodiment 1 is prepared
| 0 month | 3 months | 6 months | 9 months | 12 months | 18 each months | |
| Character | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of |
| Content | 100.3％ | 100.1％ | 100.2％ | 100.3％ | 101.0％ | 99.8％ |
| Granularity | Qualified | Qualified | Qualified | Qualified | Qualified | Qualified |
| Limit test of microbe | 200/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 300/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 270/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 300/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 260/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 210/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect |
The granule long term test study on the stability result that table 5 embodiment 2 is prepared
| 0 month | 3 months | 6 months | 9 months | 12 months | 18 each months | |
| Character | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of |
| Content | 100.1％ | 100.7％ | 99.6％ | 100.6％ | 99.6％ | 100.1％ |
| Granularity | Qualified | Qualified | Qualified | Qualified | Qualified | Qualified |
| Limit test of microbe | 410/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 300/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 270/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 300/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 260/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 260/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect |
The granule long term test study on the stability result that table 6 embodiment 4 is prepared
| 0 month | 3 months | 6 months | 9 months | 12 months | 18 each months | |
| Character | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of | This product is a white particle, gas fragrance; It is sweet to distinguish the flavor of |
| Content | 100.9％ | 100.3％ | 99.8％ | 100.1％ | 99.6％ | 99.9％ |
| Granularity | Qualified | Qualified | Qualified | Qualified | Qualified | Qualified |
| Limit test of microbe | 360/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 380/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 270/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 200/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 310/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect | 320/g of antibacterial mycete＜10/g control bacterium, the demodicid mite that lives do not detect |
Conclusion (of pressure testing): show by above data, ibuprofen granule of the present invention in long-term experiment, every index all with the test before no significant difference, steady quality.
Claims (4)
1. brufen pellet, this granule is made by the ibuprofen of 20 weight portions and the adjuvant of 80 weight portions, it is characterized in that described adjuvant is grouped into by the one-tenth of following weight portion: dextrin 60-75 part, hyprolose 2-10 part and sodium cyclamate 1-7 part.
2. according to the brufen pellet of claim 1, it is characterized in that described adjuvant is grouped into by the one-tenth of following weight portion: 5 parts of 70 parts in dextrin, 5 parts of hyprolose and sodium cyclamate.
3. method for preparing claim 1 brufen pellet, step is as follows:
With dextrin, hyprolose and sodium cyclamate grinding and sieving, add the ibuprofen mix homogeneously; Make soft material with purified water, make 16 order granules again; The vacuum condensation drying, 14 order granulate promptly.
4. according to the method for claim 3, it is characterized in that dextrin, hyprolose and sodium cyclamate are pulverized the back crosses 120 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100907522A CN100500144C (en) | 2005-08-15 | 2005-08-15 | Ibuprofen granule and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100907522A CN100500144C (en) | 2005-08-15 | 2005-08-15 | Ibuprofen granule and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1919189A true CN1919189A (en) | 2007-02-28 |
| CN100500144C CN100500144C (en) | 2009-06-17 |
Family
ID=37777130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100907522A Expired - Fee Related CN100500144C (en) | 2005-08-15 | 2005-08-15 | Ibuprofen granule and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100500144C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389401A (en) * | 2011-11-22 | 2012-03-28 | 陆荣政 | Dexibuprofen particles and preparation method thereof |
-
2005
- 2005-08-15 CN CNB2005100907522A patent/CN100500144C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389401A (en) * | 2011-11-22 | 2012-03-28 | 陆荣政 | Dexibuprofen particles and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100500144C (en) | 2009-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101167749B (en) | Preparing method for improving toad venom taste | |
| CN1161650A (en) | Process for making dosage units by wet granulation | |
| CN100342848C (en) | Effervescence tablet for reducing fever comprising tropaeolum and process for preparing the same | |
| CN102988993A (en) | Screening and composition of main auxiliary materials of compound acetaminophen tablet, and preparation method of compound acetaminophen tablet | |
| CN112618493B (en) | Bromhexine hydrochloride soluble powder for livestock, preparation method and application | |
| CN103040784A (en) | Montelukast tablet composition and preparation method thereof | |
| CN117064939B (en) | Pudi blue anti-inflammatory capsule and preparation method thereof | |
| CN1919189A (en) | Ibuprofen granule and preparing method thereof | |
| CN117180337A (en) | Preparation method of Mongolian medicine raspberry wood formula particles and fingerprint construction method thereof | |
| CN103435496A (en) | Bromhexine hydrochloride compound, and preparation method, medicinal composition and preparation thereof | |
| CN101612138B (en) | Cefetamet pivoxil hydrochloride capsule and preparation method thereof | |
| CN100353943C (en) | Fleroxacin lactate dispersion tablet, and its prepn. method | |
| CN101683325A (en) | Cydiodine buccal tablets and preparation method thereof | |
| CN1836673A (en) | Chinese medicinal soft capsule and method for preparing and controlling the quality of Chinese medicinal soft capsule | |
| CN1850059B (en) | Amlexanox oral membrane, and its preparing method | |
| CN1507862A (en) | Complex acetaminophen vitamin C dispersion tablet and preparing method thereof | |
| CN108524458A (en) | Drug and preparation method thereof | |
| CN111228357A (en) | Chaiyin micro-pill preparation and preparation method thereof | |
| CN1331476C (en) | Method for preparing coenzyme-A sublingual lozenge | |
| CN1235576C (en) | Slow-released dosage form of sodium ferulate and preparation process thereof | |
| CN1739575A (en) | Solid and liquid attapulgite prepn for treating digestive tract diseases | |
| CN109846905A (en) | A kind of preparation method of infant paracetamol and amantadine hydrochloride particles | |
| CN110840871A (en) | Composition containing p-aminobenzoic acid derivative and aliphatic six-membered cyclic carboxylic acid derivative and application thereof | |
| CN107998091A (en) | A kind of montelukast sodium tablet and preparation method thereof | |
| CN101091738A (en) | Composition of medicine in use for treating cardiovascular disease and cerebrovascular disease, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: AN BANGTAO Free format text: FORMER OWNER: HAERBIN HUARUI BIOCHEMISTRY PHARMACEUTICAL LNDUSTRY Effective date: 20110930 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 150025 HARBIN, HEILONGJIANG PROVINCE TO: 150001 HARBIN, HEILONGJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110930 Address after: 150001, 2 units, 703 doors, 8 District, 1st Street, 1st Street, Nangang District, Harbin, Heilongjiang Patentee after: An Bangtao Address before: 150025 Shanghai street Heilongjiang city Harbin province Limin economic and Technological Development Zone No. 7 Patentee before: HARBIN HUARUI BIOCHEMICAL PHARMACEUTICAL CO.,LTD. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090617 Termination date: 20210815 |